Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. PANTS study supports infliximab biosimilar use for Crohn’s disease
  2. Can Takeda’s Entyvio Be a first-line biologic For UC treatment?
  3. Checkpoint inhibitors continue to show benefits in a range of tumours
  4. Back to the future: old antibiotic compounds offer new hope in the fight against antibiotic resistance
  5. Cancer cachexia trial design: lack of consensus on endpoints

Latest Content

Aimmune reports positive results in PALISADE trial

Aimmune Therapeutics has reported that it has met its primary endpoint in a Phase III PALISADE trial, successfully evaluating the safety and efficacy of AR101 for the treatment of patients with a peanut allergy. 

Can Takeda’s Entyvio Be a first-line biologic For UC treatment?

At the 13th Congress of the European Crohn’s and Colitis Organization (ECCO) – Inflammatory Bowel Diseases (IBD) in Vienna, Austria, which took place from February 14–17, Takeda announced real-world data that evaluated the effectiveness of Entyvio (vedolizumab) versus tumor necrosis factor (TNF) alpha inhibitors for patients suffering from moderate to severe ulcerative colitis (UC).

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top